|
innovation for health & wellness |
|
The use of humanized recombinant monoclonal antibodies in certain diseases as biopharmaceuticals elicits the question of effectiveness in each individually treated person. We offer specific ELISA kits for the quantitative determination TNF blockers and Anti-TNF blockers (infliximab, adalimumab and etanercept). Monitoring drug levels and antibodies plays an emerging role in the management of lack- or loss of response to recombinant and/or humanized antibodies (i.e., to confirm treatment continuation, adjustment to dose, or provide a rationale for switching to another agent or to a different class of biological agent).
pharmacokinetic studies Researchers can also estimate infliximab, etanercept, adalimumab and bevacizumab levels in human, mouse, rat and monkey serum samples for pharmacokinetic studies by using relevant Matriks Biotek ELISA kits.
Several molecules are in R&D phase in the prospect of our companies research interests (for more please refer to R&D section). |
|
Specializing in testing humanized and/or recombinant antibodies, we offer ELISA kits* for the quantitative/qualitative determination of:
TNF, TNF blockers and anti-TNF blockers ELISA kits and VEGF blocker and anti-VEGF blockers ELISA kits
1. ELISA for the quantitative determination of Bevacizumab (Avastin®) 2. ELISA for the qualitative determination of anti-Bevacizumab (Avastin®) antibodies
|
|
Meet us @
BIO International Convention Booth # 3467, Hall B Turkey Pavillon
Send an e-mail to Dr. Haluk Ataoglu if you want to schedule a meeting
halukataoglu@matriksbiotek.com
|
|
Our products have been used with confidence in 24 countries by various clinical researchers and by 25 pharmaceutical companies for different purposes including biosimilar work. |
|
Cosmo Bio LTD is our new partner, to sell our products in JAPAN
|
|
* For research use only |